Laborie's Commitment to Maternal Health Innovation
The JADA System for treating abnormal postpartum uterine bleeding now joins Laborie's offerings, amplifying the company's dedication to enhancing maternal health.
Transforming Obstetrics Portfolio with JADA System
Laborie Medical Technologies Corp, widely known as Laborie, has successfully completed the acquisition of the JADA System. This event is a significant step in expanding its obstetric portfolio and signifies a major milestone in the realm of maternal healthcare. The JADA System is an FDA-cleared device specifically designed for rapid control and treatment of abnormal postpartum uterine bleeding. This innovative addition aligns with Laborie's goal of transforming the patient experience by providing effective solutions aimed at improving maternal health and safety.
Addressing Postpartum Hemorrhage Challenges
Postpartum hemorrhage (PPH) represents one of the most pressing concerns in childbirth. It is recognized as the primary cause of maternal mortality across the globe. Millions of women encounter this serious issue each year, contributing to over 20% of maternal deaths. The JADA System is introduced to target this urgent challenge, bringing hope to both healthcare providers and mothers alike.
A Mission Focused on Health and Safety
According to Nikki Bruce, Laborie's Vice President and General Manager of OB, the JADA System equips care teams with the necessary tools to tackle issues during critical moments in childbirth—times when immediate response is paramount. The commitment of Laborie's OB unit has always been to ensure that every mother and newborn returns home healthy. The acquisition of the JADA System only serves to reinforce this promise and reflects their unwavering passion for advancing maternal health on a global scale.
Growth Through Strategic Acquisition
This strategic acquisition not only brings the JADA System into Laborie's fold but also introduces a more extensive team of over 90 new colleagues, predominantly in commercial roles. Such an expansion signifies Laborie's ambition to bolster its capabilities in the obstetrics sector and improve the standard of care delivered to both clinicians and their patients.
Strategic Alignment with Company Goals
Chris Smith, Laborie's President and CEO, expressed excitement regarding this significant milestone for their OB business. He emphasized that welcoming the JADA System and its team marks a pivotal moment in Laborie's journey, enhancing their commitment to providing superior care in obstetrics. Smith reiterated how this acquisition aligns seamlessly with the company's ongoing mission of elevating healthcare standards worldwide.
Clinical Validation of the JADA System
Supported by numerous clinical studies underscoring its safety and efficacy, the JADA System employs a low-level vacuum mechanism that helps trigger natural uterine contractions, effectively controlling bleeding. This revolutionary device has already aided over 136,000 mothers in more than 20 countries, making vacuum-induced postpartum hemorrhage care a recognized approach in the field of obstetrics.
Commitment to Maternal Health Worldwide
Sofia Gerard, Managing Director at Patricia Industries, which owns Laborie, expressed her pride in welcoming the JADA System into the organization. This addition signifies Laborie's commitment to improving maternal health outcomes globally and brings forth a proven solution that complements their existing maternal health technologies. The collaboration is poised to enhance the support provided to caregivers and mothers worldwide.
Future Vision for Laborie and Maternal Health
The excitement surrounding the acquisition reflects the broader goals of Patricia Industries, which aims to accelerate growth and empower companies like Laborie to fulfill their impactful missions. Combining the innovation of the JADA System with Laborie's established expertise creates opportunities for introducing advanced treatment options for caregivers and mothers around the globe. This acquisition illustrates the strategic focus of Patricia Industries on building sustainable businesses that generate societal value through innovation.
Frequently Asked Questions
What is the JADA System?
The JADA System is an FDA-cleared device designed for the rapid control and treatment of abnormal postpartum uterine bleeding, addressing postpartum hemorrhage effectively.
Why is postpartum hemorrhage a concern?
Postpartum hemorrhage is the leading cause of maternal mortality worldwide, claiming millions of lives annually. The JADA System provides a critical solution to this urgent healthcare challenge.
How does the acquisition benefit Laborie?
This acquisition enhances Laborie's obstetrics portfolio by integrating innovative technology and an experienced team, ultimately aiming to improve maternal health outcomes.
What impact does Laborie's growth have on maternal care?
Laborie's strategic growth aims to elevate standards in maternal care and ensure that mothers and newborns receive the best possible support during and after childbirth.
What are the future plans for Laborie following this acquisition?
Following the acquisition of the JADA System, Laborie plans to focus on expanding its offerings and reinforcing its commitment to enhancing maternal health through innovative solutions.
